Monthly Archives: March 2018

Genprex Announces Pricing of Initial Public Offering of Common Stock

AUSTIN, Texas, March 29, 2018 /PRNewswire/ — Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 per share, before underwriting discounts. 

Read More

IPO alert: Cancer-fighting startup Genprex raises millions going public to fund new treatments

Lead product, Oncoprex, is an injectable treatment for lung cancer.

Read More